Comparison of two different strategies of treatment with zoledronate in <scp>HIV</scp>‐infected patients with low bone mineral density: single dose versus two doses in 2 years

Abstract

The benefits for BMD of a single dose of zoledronate in 2 years may be comparable to those obtained with two doses of the drug after 96 weeks, although this study is insufficiently powered to exclude a real difference. Future studies should explore whether biennial administration of zoledronate is a useful alternative in the treatment of osteoporosis in HIV-infected patients.